MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company ROE Ratio 2011-2026 | BMY
Annual ROE Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.19 | -54.78 | 27.27 | 20.37 | 19.46 | -23.84 | 6.65 | 34.83 | 8.5 | 27.26 | 10.85 | 13.38 | 16.82 | 14.37 | 23.38 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.19 | -54.78 | 12.18 |
Quarterly ROE Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.58 | -41.17 | -48.64 | -49.23 | -51.99 | 25.16 | 23.42 | 20.99 | 13.01 | 17.16 | 12.36 | 15.22 | 12.39 | -14.12 | -13.32 | -16.41 | -23.84 | 0.63 | -1.7 | 1.3 | 6.66 | 16.98 | 27.91 | 27.79 | 35.07 | 6.97 | 0.62 | 5.76 | 8.58 | 33.93 | 34.16 | 33.57 | 27.55 | 20.64 | 18.16 | 10.04 | 10.97 | 12.44 | 12.34 | 15.5 | 13.49 | 18.2 | 17.91 | 19.2 | 16.91 | 18.91 | 9.13 | 10.32 | 14.39 | 12.94 | 24.23 | 25.15 | 23.25 | 6.07 | 5.65 | 6.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.58 | -51.99 | 9.42 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
Processa Pharmaceuticals
PCSA
|
-243.2 | $ 2.3 | -1.29 % | $ 3.01 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 220.9 | 2.49 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.57 | 1.77 % | $ 915 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Phathom Pharmaceuticals
PHAT
|
50.49 | $ 10.47 | 4.08 % | $ 763 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Pliant Therapeutics
PLRX
|
-82.42 | $ 1.31 | 2.34 % | $ 80.4 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
-74.24 | $ 1.37 | -1.44 % | $ 72 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.33 | 0.76 % | $ 339 M | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 8.31 | 1.59 % | $ 111 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 47.09 | 1.42 % | $ 4.23 B |  Schweiz |
 |
Cyclacel Pharmaceuticals
CYCC
|
515.73 | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
-144.96 | $ 3.26 | 4.49 % | $ 251 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.58 | - | - | $ 2.02 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-54.47 | $ 1.58 | 6.04 % | $ 99.5 M |  Niderland |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Palatin Technologies
PTN
|
362.3 | $ 21.0 | 5.79 % | $ 19.5 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Pulmatrix
PULM
|
-135.49 | $ 2.12 | -1.4 % | $ 7.74 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.53 | 5.1 % | $ 868 M | Canada |
 |
Homology Medicines
FIXX
|
70.98 | - | 0.77 % | $ 53.4 M | USA |